Jia Lee
Developmental Therapeutics Program, National Cancer Institute, National Institutes of Health, Rockville, MD 20852, USA.
Curr Nanosci. 2005 Nov 1;1(3):237-243. doi: 10.2174/157341305774642939.
The increasing frequency at which poorly soluble new chemical entities are being discovered raises concerns in the pharmaceutical industry about drugability associated with erratic dissolution and low bioavailability of these hydrophobic compounds. Nanonization provides a plausible pharmaceutical basis for enhancing oral bioavailability and therapeutic effectiveness of these compounds by increasing their surface area. This paper surveys methods available to pharmaceutical manufacturing nanoparticles, including wet chemical processes, media milling, high pressure homogenization, gas-phase synthesis, and form-in-place processes, and elaborates physicochemical rational and gastrointestinal physiological basis upon which nano-drugs can be readily absorbed. Relevant examples are illustrated to show that nano-drugs permeate Caco-2 cell monolayer fast and are well absorbed into animal systemic circulation with high T(max) and AUC, resulting in oral bioavailability higher than their counterpart micro-drugs. The size-dependent permeability and bioavailability should be given particular consideration in the development of potent and selective drug candidates with poor aqueous solubility.
越来越多难溶性新化学实体的发现频率,引发了制药行业对这些疏水性化合物因溶解不稳定和生物利用度低而导致的成药性的担忧。纳米化通过增加难溶性化合物的表面积,为提高其口服生物利用度和治疗效果提供了一个合理的药学基础。本文综述了制药领域制备纳米颗粒的可用方法,包括湿化学法、介质研磨法、高压均质法、气相合成法和原位成型法,并阐述了纳米药物易于吸收的物理化学原理和胃肠生理学基础。文中列举了相关实例,表明纳米药物能快速透过Caco-2细胞单层,并以较高的T(max)和AUC被很好地吸收进入动物体循环,从而使其口服生物利用度高于相应的微米药物。在开发水溶性差的强效和选择性候选药物时,应特别考虑粒径依赖性通透性和生物利用度。